Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase ll Trial of Docetaxel/Pembrolizumab Combination Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT05252429 is registered in ClinicalTrials.gov with Hokkaido University Hospital as lead sponsor.

NCT NCT05252429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05252429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase ll Trial of Docetaxel/Pembrolizumab Combination Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
Hokkaido University Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 6, 2022
Completion date
November 30, 2025
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effect of drug